Last reviewed · How we verify
Formulation A: OnabotulinumtoxinA
At a glance
| Generic name | Formulation A: OnabotulinumtoxinA |
|---|---|
| Also known as | BOTOX, OnabotulinumtoxinA |
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- AI-09 In Subjects With Glabellar Lines, GL-101 (PHASE1, PHASE2)
- A Study Comparing the Safety, Efficacy, and Diffusion of Letibotulinum Toxin A Versus Other Botulinum Toxin Products in Adults With Moderate-to-Severe Forehead Wrinkles (PHASE4)
- Evaluation of Tibial Nerve Selective Neurotomy Compared to Botulinum Toxin Injections for Spastic Foot Treatment in Post-stroke Patients According to a Goal-centered Approach (NA)
- A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines (PHASE2)
- The Effects of Waning of Botulinum Toxin in the Treatment of Cervical Dystonia (PHASE4)
- Assessment of Long-term Clinical Response to BoNT in Cervical Dystonia
- Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study (PHASE4)
- OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Formulation A: OnabotulinumtoxinA CI brief — competitive landscape report
- Formulation A: OnabotulinumtoxinA updates RSS · CI watch RSS
- Allergan portfolio CI